Latest News
Interim Results for the Six Months Ended 30 June 2020
30 September 2020
Tiziana Life Sciences Interview to Air on Bloomberg International on the RedChip Money Report
25 September 2020
Issue of Equity and Total Voting Rights
21 September 2020
London, New York, 21 September 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has allotted and...
Tiziana to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in Brazil
17 September 2020
Nasal Administration of Foralumab is a potentially transformative approach for treating patients with Covid-19.
New York/London, September 17, 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for...
Tiziana Life Sciences Announces Planned Spin Out of StemPrintER into a New Publicly Listed Company, AccuStem Sciences
16 September 2020
Tiziana Shareholders to receive 1:1 share dividend in AccuStem Sciences
NEW YORK/LONDON, September 16, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases...
TR-1: Standard form for notification of major holdings
28 August 2020
|
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i |
||||||
| ... |
Notable news
Video: Eyeing phase II clinical trial in HCC patients with milciclib
Dr. Kunwar Shailubhai talks to Tip TV about Tiziana receiving approval to start Phase IIa trials to test its leading compound milciclib, a CDK inhibitor as a treatment for hepatocellular carcinoma (HCC).